Scale to predict survival after surgery for recurrent glioblastoma multiforme.

PURPOSE Despite initial treatment with surgical resection, radiotherapy, and chemotherapy, glioblastoma multiforme (GBM) virtually always recurs. Surgery is sometimes recommended to treat recurrence. In this study, we sought to devise a preoperative scale that predicts survival after surgery for recurrent glioblastoma multiforme. PATIENTS AND METHODS The preoperative clinical and radiographic data of 34 patients who underwent re-operation of recurrent GBM tumors were analyzed using Kaplan-Meier survival analysis and Cox proportional hazards regression modeling. The factors associated with decreased postoperative survival (P < .05) were used to devise a prognostic scale which was validated with a separate cohort of 109 patients. RESULTS The factors associated with poor postoperative survival were: tumor involvement of prespecified eloquent/critical brain regions (P = .021), Karnofsky performance status (KPS) < or = 80 (P = .030), and tumor volume > or = 50 cm(3) (P = .048). An additive scale (range, 0 to 3 points) comprised of these three variables distinguishes patients with good (0 points), intermediate (1 to 2 points), and poor (3 points) postoperative survival (median survival, 10.8, 4.5, and 1.0 months, respectively; P < .001). The scale identified three statistically distinct groups within the validation cohort as well (median survival, 9.2, 6.3, and 1.9 months, respectively; P < .001). CONCLUSION We devised and validated a preoperative scale that identifies patients likely to have poor, intermediate, and good relative outcomes after surgical resection of a recurrent GBM tumor. Application of this simple scale may be useful in counseling patients regarding their treatment options and in designing clinical trials.

[1]  Igor Katsyv,et al.  Experimental approaches for the treatment of malignant gliomas. , 2010, Pharmacology & therapeutics.

[2]  Alvin I Mushlin,et al.  Health care reform and the need for comparative-effectiveness research. , 2010, The New England journal of medicine.

[3]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Susan M. Chang,et al.  Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. , 2008, Journal of neurosurgery.

[6]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[7]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[8]  E. Shaw,et al.  Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[10]  M. Prados,et al.  Survival and functional status after resection of recurrent glioblastoma multiforme. , 1998, Neurosurgery.

[11]  M. Bernstein,et al.  The value of reoperation for recurrent glioblastoma. , 1993, Canadian journal of surgery. Journal canadien de chirurgie.

[12]  M. Ammirati,et al.  Reoperation in the treatment of recurrent intracranial malignant gliomas. , 1987, Neurosurgery.

[13]  P. Gutin,et al.  Reoperation for recurrent glioblastoma and anaplastic astrocytoma. , 1987, Neurosurgery.

[14]  D P Byar,et al.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.

[15]  R. Barnard,et al.  The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.